NC BioStartTranslation through Commercialization

1

Who we are

Dr. Richard Boucher Executive DirectorDon Rose, Ph.D. DirectorIlona Ori Program AssistantJustin Brown, Ph.D. Visiting Scholar, Entrepreneurship

Entrepreneurs-in-Residence• Tom Mercolino, Ph.D• Joel Shaffer, Ph.D.• Perry Genova, Ph.D.

2

Rationale

Value of University Startups• Translation through Commercialization• Faculty Recruitment and Retention• Increase Value of University Assets• Economic Development

Build on current efforts at UNC to foster startups• Launching the Venture (KFBS)• Carolina Express License (OTD)

3

Program Overview

Mission• Facilitate and accelerate University startups

Scope• Life science (drugs, devices, diagnostics, tools)

Breadth• Today: UNC-CH campus• Future: All state-supported campuses

Location and Funding• NC Translational and Clinical Sciences Institute

o Home of NIH CTSA Grant (Etta Pisano, PI)

4

DRAFT

NC BioStartNC BioStart

Tom Mercolino

PhD (UNC’88) – Microbiology & ImmunologyBS – Chemistry

Registered Patent Agent

• >25 Years in Pharma & Diagnostics R&D Management• Becton Dickinson• Johnson & Johnson

• Entrepreneur•Founder & CEO of CertiRx

7

Tom Mercolino

Representative Client Companies

• Rheomics - early• College of Arts& Sciences (Prof. Physics Department)• Re-focused technology platform to high-value applications

• Hepa Ca Dx - nascent• UNC Gillings School of Global Public Health (PhD Student)• organizing clinical proof of principle

• X-In8 - established• School of Medicine (Prof. surgery)• Id and resolution of potential patent issue in partnership with OTD

8

Joel Shaffer

Entrepreneur in Residence for Therapeutics

9

Resume

• 5 yrs at American Critical Care (DuPont)• 17 yrs at Glaxo (GW, GSK)• Business Development for Metabolic Diseases• Head of Pharmacology• High-throughput screening• Preclinical Project leader• R&D in Cardiovascular, Oncology, Urology,

Metabolic Diseases

10

Entrepreneur-in-Residence at UNC May 2009

Advising 7 UNC clients

• Enci Therapeutics• Hibernaid• Novolipid• Synereca

o (Scott Singleton, Ph.D. Med. Chem. natural prod.)

• G-zero o (Ned Sharpless, M.D. Medicine, genetics)

• Matt Redinbo, Ph.D. Chemistry, structural chemistry• Mark Zylka, Ph.D. Cell & Molecular Physiology

11

Enci Therapeutics

• Cam Patterson, M.D. and Nancy DeMore, M.D.

• Discovery of new angiogenesis factor (SFRP2)

• Developed a mouse mAb

• The antibody blunts tumor growth

• How does this target compare to VEGF?

• How do we make a human mAb for clinical testing?

12

Hibernaid

• Larry Katz, M.D.• Has studied hypothermia mechanisms for years• Ice baths improve outcome for pts with cardiac arrest

• Discovered that certain agents used in combination (unexpectedly) lower the body’s temperature set point

• Determined a fixed combination of agents will:• Lower temp by 4-5 oC• Increase survival after acute cardiac arrest in rats and

pigs• Improve CNS performance post injury

• Will this benefit patients suffering from reperfusion injury?

13

Novolipid

• Mike Hackett and Deepak Gopalakrishna• Graduate students, Pharmacy and Molecular Biology

• Discovered that they could covalently attach cytotoxic chemotherapeutic drugs to small lipids which have high affinity to albumin• Longer half-life• Less systemic toxicity of drug• No need for toxic solvents• Better tumor penetration

• Will this show superior effects in animals and humans?

14

Perry Genova

• MS, PhD Biomedical Engineering• BS EE, BME• Serial entrepreneur (IEP, Quill, Oncoscope)• Global VP – GSK (MDI business – France)• VP – Kos Pharmaceuticals • Inhaled product development including insulin• Worked for Adrian Adams (CEO – Inspire)

15

• Melanie Joy (UNC) and Marian McCord (NCSU)• Addresses large unmet need (160,000 patients)• Remove excess phosphate from blood during dialysis• High phosphate associated with morbidity and

mortality• Technology combines phosphate adsorption chemistry

with filtration science• Improved compliance, no side effects• TraCS grant supported feasibility work• TAM = 25M devices, $2.5B market

Katharos – Improving care for dialysis patients

Contact InformationDon RoseDirector, NC BioStartdonrose@email.unc.eduwww.ncbiostart.com

Ilona OriProgram Assistantilona_ori@med.unc.edu919-843-3304

Upcoming EventsCommercialization Webinar• “Incorporation and Founder’s Stock”• Ken Eheman and Anthony Williams, WRYP• March 15th, 12 – 1 pm

Emerging Company Showcase• April 12th, 6 pm, Kenan-Flagler Business School

17